D&D Pharmatech to Unveil Phase 2 DD01 Clinical Trial Results for the First Time at EASL Congress

Database Lock Completed

D&D Pharmatech, a company specializing in the development of GLP-1 (glucagon-like peptide-1) class novel drugs, announced on April 22 that it has completed the database lock for all patients following the completion of 48 weeks of dosing in the Phase 2 clinical trial of its MASH (Metabolic Dysfunction-Associated Steatohepatitis) treatment candidate 'DD01' in the United States, and has begun the procedures to derive the final results.

The 'database lock' is the stage in a clinical trial where all dosing results and safety data collected from patients are finally verified and confirmed. It is a critical procedure to ensure the data integrity of clinical data. Once this step is completed, no further modification or addition to the data is possible, and the drug’s efficacy and safety are finally validated through statistical analysis. Typically, about 30 days after the database lock, top-line data is received from the CRO.

Notably, the results of this clinical trial will be presented for the first time to medical professionals and industry experts worldwide during the Late-Breaking Abstract (LBA) session at the EASL Congress 2026, the annual meeting of the European Association for the Study of the Liver (EASL), which will be held in Barcelona, Spain starting May 27. The company expects to receive top-line data, including liver biopsy results, after mid-May following this database lock, and plans to release the finalized analysis results in line with the opening of the congress on May 27.

The lead author of this announcement is Professor Mazen Noureddin, a world-renowned expert in the MASH field and the principal investigator (PI) for this clinical trial. DD01 has already demonstrated rapid reductions in hepatic steatosis, improvements in related indicators, and potential for fibrosis improvement in previously released 12-week and 24-week dosing results. Accordingly, there is high market anticipation regarding the liver fibrosis improvement effect to be confirmed by biopsy in this 48-week long-term dosing result.

Seulgi Lee, CEO of D&D Pharmatech, stated, “The completion of the database lock signifies the successful conclusion of the 48-week long-term clinical trial, and we have now entered the final stage to validate the differentiated clinical value of DD01.” Lee added, “The fact that DD01 was selected for an LBA at EASL, even before the liver biopsy data are available, demonstrates the global academic community’s strong interest and expectations regarding the drug’s mechanism and potential.” Lee further emphasized, “Based on the 48-week liver biopsy results to be presented at this prestigious congress, we will do our utmost to achieve strategic partnering outcomes with global big pharma companies.”

This content was produced with the assistance of AI translation services.